HC Wainwright Brokers Raise Earnings Estimates for SLDB

Solid Biosciences Inc. (NASDAQ:SLDB) – Equities researchers at HC Wainwright boosted their Q1 2026 earnings per share estimates for shares of Solid Biosciences in a research note issued to investors on Monday, March 23rd. HC Wainwright analyst A. He now expects that the company will post earnings of ($0.35) per share for the quarter, up from their previous estimate of ($0.52). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Solid Biosciences’ Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.36) EPS, FY2028 earnings at ($0.60) EPS, FY2029 earnings at $0.89 EPS and FY2030 earnings at $1.81 EPS.

SLDB has been the subject of several other research reports. Needham & Company LLC reissued a “buy” rating and set a $19.00 price objective on shares of Solid Biosciences in a research report on Friday, March 20th. Wedbush reaffirmed an “outperform” rating and issued a $14.00 target price on shares of Solid Biosciences in a research report on Wednesday, March 11th. Guggenheim started coverage on shares of Solid Biosciences in a research note on Friday, March 20th. They issued a “buy” rating and a $26.00 price target for the company. Chardan Capital reissued a “buy” rating and set a $15.00 price target on shares of Solid Biosciences in a research report on Friday, March 20th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Solid Biosciences from $11.00 to $12.00 and gave the stock an “overweight” rating in a research note on Wednesday. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.09.

Solid Biosciences Stock Up 8.2%

NASDAQ SLDB opened at $7.23 on Wednesday. The firm has a market capitalization of $563.29 million, a PE ratio of -3.58 and a beta of 2.65. The stock’s 50 day moving average is $6.53 and its 200 day moving average is $5.82. Solid Biosciences has a twelve month low of $2.41 and a twelve month high of $8.72.

Solid Biosciences (NASDAQ:SLDB) last announced its earnings results on Thursday, March 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.01.

Insider Activity at Solid Biosciences

In other Solid Biosciences news, insider Gabriel Brooks sold 12,616 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $6.44, for a total transaction of $81,247.04. Following the sale, the insider directly owned 84,092 shares in the company, valued at approximately $541,552.48. This trade represents a 13.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ilan Ganot sold 7,205 shares of Solid Biosciences stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $6.44, for a total value of $46,400.20. Following the completion of the sale, the director directly owned 25,271 shares of the company’s stock, valued at approximately $162,745.24. The trade was a 22.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 597,672 shares of company stock valued at $3,816,546 over the last ninety days. Corporate insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Solid Biosciences

Institutional investors have recently modified their holdings of the business. Invesco Ltd. increased its holdings in Solid Biosciences by 29.6% in the 4th quarter. Invesco Ltd. now owns 152,126 shares of the company’s stock worth $858,000 after buying an additional 34,758 shares in the last quarter. XTX Topco Ltd bought a new position in Solid Biosciences during the 4th quarter valued at about $201,000. Vestal Point Capital LP boosted its holdings in shares of Solid Biosciences by 95.5% during the 4th quarter. Vestal Point Capital LP now owns 5,815,000 shares of the company’s stock valued at $32,797,000 after acquiring an additional 2,840,000 shares during the last quarter. Armistice Capital LLC boosted its holdings in shares of Solid Biosciences by 179.1% during the 4th quarter. Armistice Capital LLC now owns 2,612,000 shares of the company’s stock valued at $14,732,000 after acquiring an additional 1,676,000 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its stake in shares of Solid Biosciences by 168.9% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 182,869 shares of the company’s stock worth $1,031,000 after acquiring an additional 114,867 shares during the period. 81.46% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: JPMorgan raised its price target on SLDB to $12.00 from $11.00 and moved the stock to an “Overweight” stance — implying roughly a 66% upside from the referenced $7.23 level. This upgrade signals increased conviction from a large Wall Street shop and likely contributed to buying interest. Benzinga
• Positive Sentiment: HC Wainwright reiterated a “Buy” and lifted near-term EPS forecasts across multiple quarters and fiscal years (Q1–Q4 2026 and FY2026) while maintaining a $20 price target. They also issued later-year upside (FY2029–FY2030 projected profitability), trimming FY2026 losses significantly vs. prior forecasts — an analyst view that supports a more constructive growth/profitability outlook. Solid Biosciences Earns Buy Rating from HC Wainwright
• Neutral Sentiment: Reported short-interest data for March appears anomalous (shows 0 shares and NaN changes). Because the figures are likely erroneous or incomplete, they provide no clear signal about potential short-squeeze dynamics or bearish positioning at this time.

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.